ENPRA (Engineered NanoParticle Risk Assessment) was a European Framework Programme (FP) 7 project to develop and implement a novel integrated approach for engineered nanoparticle (ENP) risk assessment, which took place from 2009 - 2012.
ENPRA aimed to support long term growth and sustainability of nanotechnologies by expanding the classic exposure-dose-response paradigm of risk assessment, to develop an effective approach for the assessment and management of potential health risks from exposure to engineered nanoparticles.
The 3 ½ year project, led by the Institute of Occupational Medicine (IOM), worth €3.7 million, harnessed the knowledge and capabilities of 15 European and 6 US partners including three US Federal Agencies: EPA, NIOSH and NIH-NIEHS.
ENPRA sought to utilise the latest advances within in vitro, in vivo and in silico approaches to nanotechnology environment, health & safety (EHS) research to realise its aims. The in vitro and in silico approaches developed within ENPRA will help to reduce the need for animal experimentation in nanotoxicology. Harnessing the latest advances in toxicology to nanotechnology EH&S issues, the fundamentally novel rationale of ENPRA went beyond traditional toxicity assessment of ENP and sought to: